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856lthough saphenous vein graft (SVG) stenting is associ-
ted with high failure rates, there are limited data on the
linical presentation and angiographic patterns of SVG
ailure after stenting. Although traditionally considered a
enign event, native coronary artery in-stent restenosis
as recently reported to present with an acute coronary
yndrome (ACS) in up to 50% of patients (1,2). We
ecently reported the results of a multicenter, randomized
linical trial (SOS [Stenting Of Saphenous Vein Grafts])
hat compared a paclitaxel-eluting stent (PES) with a
imilar bare-metal stent (BMS) in SVGs (3). In this
nalysis, we sought to determine the angiographic pat-
erns and clinical presentation of SVG stent failure, as
bserved in the SOS Trial.
Methods
The design and primary results
of the SOS trial (registry identi-
fier NCT00247208) have been
published (3). Briefly, the SOS
trial was a randomized, controlled,
single-blinded, multicenter trial
designed to test the hypothesis
that implantation of a polymer-
based PES (Taxus, Boston Scien-
tific, Natick, Massachusetts) in
SVG lesions would be associated
with reduced angiographic reste-
nosis (50% of the minimum lu-
men diameter stenosis in the tar-
get SVG segment) at 12 months
compared with a similar design
BMS (Express2, Boston Scien-
tific). Patients were asked to re-
turn for repeat coronary angiog-
raphy 12 months after stent
implantation and were contacted
by phone until 24 months after
nrollment to determine whether any late cardiovascular
vents had occurred. Angiographic follow-up was available
n 80% of the treated lesions in 83% of the patients. The
attern of in-stent restenosis was reported according to the
ehran classification (4). Continuous variables were sum-
arized as mean  1 SD and discrete variables were
resented as frequencies and group percentages. The study
as approved by the institutional review board of each
articipating site, and all patients provided written informed
onsent.
a company that is developing an embolic protection device) ($10,000). Dr. Banerjee h
edical Center, Medtronic Corp., and Johnson & Johnson, and has received a research
eceived speaker honoraria from St. Jude.
bbreviations and
cronyms
CS  acute coronary
yndrome
RC  Academic Research
onsortium
MS  bare-metal stent(s)
ABG  coronary artery
ypass grafting
ES  drug-eluting stent(s)
I  myocardial infarction
STEMI  non–ST-segment
levation acute myocardial
nfarction
CI  percutaneous
oronary intervention
DA  posterior descending
rtery
ES  paclitaxel-eluting
tent(s)
VG  saphenous vein graftanuscript received March 24, 2009; revised manuscript received May 28, 2009, acceptedAcute coronary syndrome was defined as either myocar-
ial infarction (MI) or unstable angina. Myocardial infarc-
ion during follow up was defined as typical rise and fall of
roponin or creatinine kinase-myocardial band (CK-MB)
bove the upper limit of normal with either ischemic
ymptoms or electrocardiographic changes indicative of
schemia (ST-segment elevation or depression or develop-
ent of pathologic Q waves) (3). Unstable angina was
efined as typical anginal symptoms occurring in an increas-
ng pattern or at rest requiring hospital stay without eleva-
ion of troponin or CK-MB.
esults
ngiographic ﬁndings. In the BMS group, 20 of 33 patients
61%) developed angiographic restenosis in 24 of 47 lesions
51%) in 21 of 37 SVGs (57%). In the PES group, 4 of 33
atients (12%) developed angiographic restenosis in 4 of 43
esions (9%) in 4 of 35 SVGs (11%) (p  0.0001 for all
omparisons between BMS and PES).
Among patients in the BMS group with vein graft failure,
cclusion of the SVG (Fig. 1) was seen in 8 of 20 patients
40%), 8 of 21 grafts (38%), and in 11 of 24 lesions (46%)
3 patients had 2 lesions treated in the same SVG). Subtotal
bstruction (50% to 99%) was seen in 13 lesions, in 13 SVGs
n 12 patients (1 patient developed restenosis in 2 lesions
ocated in 2 SVGs). The pattern of restenosis was focal (type I)
n 9 lesions (7 were focal body-type IC, and 2 were focal
argin-type IB) (Fig. 2), diffuse intrastent (type II) in 2
esions, and diffuse proliferative (type III) in 2 lesions.
In the PES group, 4 patients each had a lesion in an
VG. Two of the 4 SVGs were occluded, and the other 2
ad focal body in-stent restenosis (type IC).
linical presentation. Ten of 24 patients (42%) with SVG
ailure presented with an ACS (Table 1). Of the 10 patients
ho developed SVG occlusion, 3 met the Academic Research
onsortium (ARC) definition for definite stent thrombosis (an
ccluded graft in the setting of an acute MI). The first patient
resented with a non–ST-segment elevation acute myocardial
nfarction (NSTEMI) complicated by ventricular fibrillation 2
eeks after stenting of an SVG to the right posterior descend-
ng artery (PDA). His initial procedure was complicated by
ecurrent chest pain and Thrombolysis in Myocardial Infarc-
ion flow grade 2 SVG the following day requiring repeat
alloon angioplasty and catheter thrombectomy (Angiojet,
ossis Medical, Minneapolis, Minnesota). Two weeks later he
epresented with an NSTEMI. On repeat coronary angiogra-
hy the SVG to PDA was found to be occluded with no other
ignificant changes from his baseline angiogram. Repeat PCI
ed on the Speakers’ Bureau for St. Jude
rom Boston Scientific. Dr. Brilakis hasJune 25, 2009.
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857f the SVG to PDA was not attempted, but native coronary
rtery PCI was performed. The second patient presented with
n NSTEMI complicated by ventricular fibrillation and was
ound to have an acute occlusion of an SVG to the right PDA
1 months after stent placement. The SVG flow was restored
ith primary PCI (Fig. 1). The third patient presented with an
STEMI 22 months after stent placement and was found to
ave an occluded SVG to the first obtuse marginal branch. He
as treated medically. The remaining 7 patients found to have
n SVG occlusion presented with unstable angina (n  1),
table angina (n  3), or were asymptomatic (n  3).
One additional patient presented initially with subtotal
n-stent restenosis but subsequently developed definite stent
hrombosis after repeat SVG PCI. This patient presented with
Figure 1. SVG Stent Thrombosis in a Patient Randomized to the BMS
Arm of the SOS Trial
A 74-year-old man presented with an ostial lesion in a 17-year-old saphenous
vein graft (SVG) supplying the right posterior descending artery (arrows, A),
which was successfully treated with implantation of a 3.0  20 mm Express2
(Boston Scientiﬁc, Natick, Massachusetts) bare-metal stent (BMS) (arrows, B)
with distal embolic protection with a Filterwire (Boston Scientiﬁc). Eleven
months after stent implantation the patient presented with a non–ST-segment
elevation acute myocardial infarction complicated by ventricular ﬁbrillation
and emergency coronary angiography demonstrated ostial SVG occlusion
(arrow, C). After implantation of a 3.0  15 mm BMS overlapping the distal
edge of the prior proximal stent and implantation of a 3.0  12 mm BMS in
the distal SVG, Thrombolysis in Myocardial Infarction ﬂow grade 3 antegrade
SVG was restored (arrows, D).table angina 12 months after randomization due to sub-total an-stent restenosis as well as a new severe stenosis more distally
n an SVG supplying the right PDA. He underwent repeat
CI of both SVG lesions, and 5 days later he developed stent
hrombosis.
All 4 cases of ARC definite stent thrombosis occurred in
atients randomized to BMS. The patient who presented with
ate stent thrombosis at 22 months had stopped clopidogrel 9
onths after randomization (13 months before the event). The
ther 3 patients with ARC definite stent thrombosis were
aking dual antiplatelet therapy at the time of the stent
hrombosis. There were 2 additional cases of probable stent
hrombosis both occurring within 1 week of randomization.
ne patient had sudden death 6 days after receiving a PES
ithout angiographic or autopsy evidence of stent thrombosis.
nother patient presented with an NSTEMI in the myocar-
ial distribution supplied by the original SVG (on the basis of
lectrocardiographic changes and new wall motion abnormal-
ties) 6 days after receiving a BMS and was managed medically,
ithout angiography. Both patients were taking dual antiplate-
et therapy at the time of the event.
Of the remaining 7 patients with occluded vein grafts (without
efinite stent thrombosis) at follow up, 4 were still taking dual
ntiplatelet therapy at the time of follow-up and 3 had stopped
lopidogrel before the discovery of the occluded SVG.
evascularization. The outcomes of repeat PCI procedures in
he SOS patients who developed SVG failure are summarized
n Table 2. None of the 5 asymptomatic patients with SVG
ailure at follow-up angiography underwent a repeat revascu-
arization procedure. Seventeen of the 19 symptomatic patients
nderwent repeat revascularization of 20 failed SVGs. Twelve
f the 19 patients had subtotal in-stent restenosis within 13
rafts and were all treated with repeat PCI (1 BMS patient
eveloped SVG restenosis in 2 SVGs, both of which under-
ent repeat stenting with a PES). The remaining 7 symptom-
tic patients (3 of whom had initially undergone treatment of
lesions in the target SVG) had occluded grafts. Only 1 of
hese patients (who presented with stent thrombosis) (Fig. 1)
nderwent repeat SVG PCI. Four patients underwent PCI of
native artery supplying the territory originally supplied by the
ccluded SVG (3 at the time of follow-up angiography and 1
t 4 months after angiography when medical therapy failed to
ontrol his angina). The remaining 3 symptomatic patients
ith occluded SVGs received medical therapy alone.
iscussion
he most important findings of this study are that failure after
VG stenting: 1) frequently presents with an acute MI; and
) is often due to SVG occlusion.
Although in-stent restenosis has traditionally been consid-
red a low-risk event, recent studies have shown that this might
ot be true. Chen et al. (1) reported that, among 1,186 cases of
MS restenosis at the Cleveland Clinic, 36% presented with
n ACS (26% unstable angina and 10% with MI). In that
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858tudy, prior coronary artery bypass grafting (CABG) was an
ndependent predictor of development of an ACS, although
hether that was due to restenosis within an SVG was not
eported (11.3% of the target vessels were SVGs). Similarly,
teinberg et al. (2) reported that restenosis within a BMS
resented with an acute MI in 6.7% and with unstable angina
n 47% of 2,539 patients at the Washington Hospital Center.
n the SOS trial, nearly one-third of the patients who devel-
ped SVG stent failure presented with an acute MI, which was
artly due to the high frequency of ARC definite/probable
tent thrombosis (6 of 80 patients, 7.5%, 5 of whom were
aking dual antiplatelet therapy at the time of the event). This
Figure 2. SVG Focal In-Stent Restenosis in a Patient Randomized to the BM
A 64-year-old man presented with an ostial lesion in a 28-year old SVG supply
with implantation of a 3.0  24 mm Express2 (Boston Scientiﬁc) BMS (arrows,
later the patient returned with symptoms of exertional angina and was found
implantation of a 3.0  24 mm paclitaxel-eluting stent (arrows, D). Abbreviati
Table 1. Clinical Presentation of Stent Failure in the SOS Trial
Presentation Total Patients BMS Patients PES Patients
ACS 10 (42%) 7 (35%) 3 (75%)
NSTEMI 7 (29%) 6 (30%) 1 (25%)
UA 3 (13%) 1 (5%) 2 (50%)
Stable angina 9 (37%) 9 (45%) 0 (0%)
Asymptomatic 5 (21%) 4 (20%) 1 (25%)
Values are n (%).
ACS  acute coronary syndrome; BMS  bare-metal stent(s); NSTEMI  non–ST-segmentelevation acute myocardial infarction; PES paclitaxel-eluting stent(s); UA unstable angina.ould explain the high mortality (5% to 7%/year) and risk of
I in patients with prior CABG undergoing diagnostic
ngiography (5) or PCI (6). Administration of dual antiplatelet
herapy was similar in the 2 SOS study groups (3), likely
ecause most patients initially presented with an ACS. Yet, in
iew of the high risk for developing an ACS after SVG stent-
ng, prolonged dual antiplatelet therapy should be considered.
All patients developing acute MI during follow-up, includ-
ng all 4 patients with definite stent thrombosis, presented with
n NSTEMI. The lack of ST-segment elevation in these cases
s likely secondary to partially preserved antegrade coronary
m of the SOS Trial
e left anterior descending artery (arrow, A), which was successfully treated
th distal embolic protection with a Filterwire (Boston Scientiﬁc). Five months
e in-stent restenosis (arrow, C), which was successfully treated with
in Figure 1.
Table 2. Coronary Revascularization in Asymptomatic and Symptomatic
Patients Participating in the SOS Trial
Presentation
Number of
Failed SVGs SVG PCI
Native Coronary
Artery PCI
Asymptomatic 5
100% SVG occlusion 3 0 0
Subtotal SVG occlusion 2 0 0
Symptomatic 20
100% SVG occlusion 7 1 4
Subtotal SVG occlusion 13 13 0S Ar
ing th
B) wi
to havPCI percutaneous coronary intervention; SVG saphenous vein graft.
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859ow and more developed collateral flow in patients with prior
ABG, although it might also be associated with failure of
VGs to an obtuse marginal branch (in 2 of the 7 NSTEMI
atients in our study).
In native coronary arteries, in-stent restenosis causes vessel
cclusion in 1% of patients, whether a DES or a BMS is
sed (7,8). In contrast, occlusion after stent placement in an
VG is not rare. The 6-month occlusion rates of a BMS
laced in an SVG was 13% in the SAVED (Saphenous Vein
e Novo Trial Investigators) trial (9), 13% in the Venestent
rial (10), 7% in the STING (STents IN Grafts) trial (11),
2.5% in the RRISC (Reduction of Restenosis In Saphenous
ein grafts with Cypher sirolimus-eluting stent) trial (12), 8%
n a study by Hoffman et al. (13), and 11.5% in a study by
ohrle et al. (14). The rate of SVG occlusion in the BMS arm
f the SOS trial (23% of treated lesions) is somewhat higher
han the aforementioned studies, most likely because follow-up
ngiography was performed after 12 rather than 6 months,
hich illustrates that SVG failure risk might remain high even
eyond 6 months. In the SOS trial, although restenosis
ccurred significantly less often in PES-treated than in BMS-
reated patients, SVG occlusion occurred in one-half (2 of 4) of
he PES restenotic lesions.
The high rates of SVG occlusion seen in the SOS trial could
e related to a local prothrombotic state caused by slow
ntegrade flow in the setting of in-stent restenosis (15) or to
therosclerosis progression in nonstented SVG segments (16).
oderate SVG lesions might rapidly progress to severe
16,17). Ellis et al. (16) reported the rate of long-term (29 13
onths) ischemic events in untreated nonobstructive SVG
esions. Saphenous vein graft lesions with 41% to 50%, 31% to
0%, and 30% diameter stenosis at baseline were associated
ith a 45%, 18%, and 2% incidence, respectively, for ischemic
vents at follow-up (16). Rodés-Cabau et al. (17) evaluated
redictors of SVG lesion progression in 86 patients with
ntreated nonobstructive SVG lesions at baseline who had
linically driven angiographic follow-up after 20 15 months.
n multivariate analysis, predictors of angiographic progres-
ion (0.6 mm decrease in minimal luminal diameter or
10% increase in maximal diameter stenosis) were baseline
igh-density lipoprotein cholesterol and the SVG atheroscle-
otic burden score; the only predictor of clinical events related
o SVG disease progression was maximal percent SVG diam-
ter stenosis at baseline (17). The DES are unlikely to affect
VG atherosclerosis progression outside the stented SVG
egment and might paradoxically be associated with higher
ates of nontarget SVG lesion progression. If a stented SVG
egment remains patent, lesions in nonstented segments might
rogress, whereas if the SVG occludes due to failure of the
tented segment no further SVG failure is possible. This might
xplain why in the PES arm of the SOS trial target lesion
evascularization was dramatically reduced, whereas there was
nly a trend for lower target vessel revascularization (3): indeed,
arget SVG revascularization was due to progression of SVGtherosclerosis outside the stented segment in 4 of 6 (66%)
uch patients in the PES arm versus in only 1 of 12 (8%) such
atients in the BMS arm (3).
Treating SVG occlusions is challenging, whether the occlu-
ion is acute or chronic, and angiographic success might not
orrelate with improved clinical outcomes (18). According to
he 2005 American College of Cardiology/American Heart
ssociation PCI guidelines, “PCI is not recommended in
atients with prior CABG for chronic total vein graft occlu-
ions” (Class III indication) (19). Acute SVG occlusions are
sually associated with large thrombus burden, often necessi-
ating stenting of a long length of the SVG to restore patency.
atients with chronic SVG occlusions and medically refractory
ymptoms might be best treated with PCI of the native
oronary artery, when technically feasible (20,21); yet this
ight be challenging, due to the high prevalence of chronic
cclusions in the native coronary arteries of prior CABG
atients. In view of the poor short- and long-term outcome
fter PCI of occluded vein grafts (19), prevention of SVG
cclusion is of paramount importance. On the basis of the SOS
rial, PES implantation provides significant clinical benefit
ompared with BMS implantation not only at reducing overall
VG failure but also of reducing occlusion, although large
tudies are needed to determine the long-term clinical benefits
f placing DES in SVGs (22,23).
This study is primarily limited by the relatively small
umber of patients enrolled and incomplete angiographic
ollow-up, although the SOS trial obtained 12-month angio-
raphic follow-up data in contrast to 6-month follow-up data
rovided by most previous studies. The mandatory angio-
raphic follow-up could have increased the rates of repeat
evascularization, although none of the asymptomatic pa-
ients with SVG restenosis were revascularized (Table 2). In
he SOS trial the interventional cardiologists and physicians
reating the patients were not blinded to stent assignment,
et the patients and outcome assessors were blinded (3).
onclusions
VG stent failure often presents as acute MI and with SVG
cclusion. Therapies that might prevent SVG in-stent
estenosis, such as DES, markedly reduce the probability of
VG failure and occlusion and could significantly improve
he clinical outcomes of patients undergoing SVG PCI.
eprint requests and correspondence: Dr. Emmanouil S.
rilakis, Dallas VA Medical Center (111A), 4500 South Lancaster
oad, Dallas, Texas 75216. E-mail: esbrilakis@yahoo.com.
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